Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12...1314151617181920212223...2425»
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    The use of Autologous Haematopoietic Stem Cell Transplants in patients with Relapsing Remitting Multiple Sclerosis (RRMS): A Meta‐Analysis () -  May 14, 2020 - Abstract #BSH2020BSH_444;    
    Objective To investigate the safety and efficacy of administering autologous haematopoietic stem cell transplants (AHSCT) in patients who have been diagnosed with relapsing remitting multiple sclerosis (RRMS) as an alternative to current disease modifying therapies (DMTs) such as Alemtuzumab and Interferons...The benefits are seen particularly in younger patients, particularly those with a lower EDSS, a shorter disease duration and patients who have not yet progressed to secondary progressive MS. With this study along with additional trials, particularly with adverse effects and long‐term outcomes beyond 5 years as primary outcomes, it is hoped that AHSCT with become a mainstream treatment for patients with early‐stage RRMS.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Review, Journal:  Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. (Pubmed Central) -  Apr 17, 2020   
    Among continuously applied regimens, interferons and glatiramer acetate act as immunomodulators, while dimethyl fumarate, fingolimod, ocrelizumab, natalizumab and teriflunomide are associated with continuous immunosuppression...A short treatment course of a pharmacologic agent hypothesized to act as an IRT, such as Cladribine Tablets 3.5 mg/kg or alemtuzumab, can provide long-term suppression of MS disease activity, without need for continuous treatment (the anti-CD20 mechanism of ocrelizumab has the potential to act as an IRT, but is administered continuously, at 6-monthly intervals)...The introduction of IRT-like disease-modifying drugs (DMDs) challenges the traditional maintenance/escalation mode of treatment and raises new questions about how disease activity is measured. In this review, we consider a modern classification of DMDs for MS and its implications for the care of patients in the IRT era.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Tysabri (natalizumab) / Biogen, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Pre-treatment with Natalizumab Reduces Risk of Alemtuzumab-Associated Secondary B-Cell Autoimmunities (Room Seville) -  Apr 9, 2020 - Abstract #EAN2020EAN_1671;    
    Alemtuzumab safety through Y1 was generally consistent with the pivotal studies. We show that pre-treatment with NAT appears to substantially lower the incidence of ALEM-associated secondary autoimmunities, most likely by making precursor B-cells, including autoreactive clones, accessible to a subsequent CD52 depletion.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Alemtuzumab-induced thyroid disease: observational data from an Italian cohort of patients (Room Seville) -  Apr 9, 2020 - Abstract #EAN2020EAN_1670;    
    A further increase in AITD has not yet emerged after two years due to a low proportion of patients with a longer follow-up. Based on our experience and in line with current recommendations, a strict thyroid-function monitoring prior and after alemtuzumab is fundamental, in order to detect and treat AITD promptly and have favorable outcomes.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Safety of Alemtuzumab in RRMS Patients in the Period Following Lymphocyte Repopulation: Clinical Trial and Postmarketing Experience (CbW Room) -  Apr 9, 2020 - Abstract #EAN2020EAN_1650;    
    P3, P4
    Based on our experience and in line with current recommendations, a strict thyroid-function monitoring prior and after alemtuzumab is fundamental, in order to detect and treat AITD promptly and have favorable outcomes. AEs occurring after lymphocyte repopulation in RRMS patients treated with alemtuzumab have included thyroid disorders, immune thrombocytopaenia, autoimmune nephropathies, and acute acalculous cholecystitis in clinical trials, and rare postmarketing cases of AIH and HLH.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Safety of Alemtuzumab Over 9 Years in Patients With Non-MS Autoimmunity (ePoster) -  Apr 9, 2020 - Abstract #EAN2020EAN_644;    
    P2, P3, P4
    Extended period of observation in a larger patient population will help further confirm its safety and efficacy. Preexisting non-MS autoimmunity was not associated with subsequent new AIAE occurrence up to 9 years after alemtuzumab initiation.
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] Association of sarcoidosis and multiple sclerosis: an important lesson in neuroimmunology (ePoster) -  Apr 9, 2020 - Abstract #EAN2020EAN_640;    
    We postulate that the state of mild immuno- suppression, lymphopenia and normal or increased levels of 1,25 OH-vitamin D3 in sarcoidosis is protective against disease activity in MS. This is supported by the low incidence of MS in patients with sarcoidosis, and development of acute sarcoidosis reported in patients with MS following treatment with beta-interferon, alemtuzumab and daclizumab, probably from a shift of immune response and macrophage activity.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono
    Trial completion date, Trial primary completion date:  TREAT-MS: Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (clinicaltrials.gov) -  Apr 6, 2020   
    P=N/A,  N=900, Recruiting, 
    This study confirmed clinical and MRI efficacy of alemtuzumab in a real life setting. Trial completion date: Oct 2022 --> Aug 2023 | Trial primary completion date: Oct 2022 --> Aug 2023
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Cytomegalovirus primary infection in a patient with multiple sclerosis treated with alemtuzumab. (Pubmed Central) -  Apr 4, 2020   
    It produces rapid depletion of T and B lymphocytes, which could predispose to opportunistic infections. We report one patient with MS who develops cytomegalovirus (CMV) primary infection after a third cycle of alemtuzumab, with spontaneous recovery associated with rapid lymphocyte reconstitution.
  • ||||||||||  Mavenclad (cladribine) / EMD Serono, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Immunological consequences of "immune reconstitution therapy" in multiple sclerosis: A systematic review. (Pubmed Central) -  Apr 4, 2020   
    Alemtuzumab may produce greater depletion of both CD4+ and CD8+ T cells than cladribine tablets, although both treatments similarly deplete B cells...Ocrelizumab and rituximab require regular repeated treatment every 6 months to maintain depletion of B and T cells...Additional characterization of the cellular changes occurring during IRT and CD20 depletion may lead to further improvement in the understanding of the pathogenesis of MS and the future development of therapies with even longer lasting effects. Although the treatments considered in this review improve quality of life and outcomes for patients with MS, a cure for this debilitating disease is not yet in sight.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Biomarker, Clinical, Journal:  A 24-month advanced magnetic resonance imaging study of multiple sclerosis patients treated with alemtuzumab. (Pubmed Central) -  Mar 23, 2020   
    This observation validates anti-CD20 therapy as a potential treatment option in patients with autoimmune complications of alemtuzumab that are postulated to arise as a result of B cell hyperpopulation. Advanced MR biomarkers of myelin (MWF) and neuron/axons (NAA) show no change in NAWM over 24 months in alemtuzumab-treated MS participants.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Data of safety in a single-center alemtuzumab treated population. (Pubmed Central) -  Mar 19, 2020   
    These events were ranked as severe in 23% of the patients. We reported, in particular, cases of autoimmune hemolytic anemia (AIHA), pancytopenia, viral hepatitis E and noninfectious meningo-encephalomyelitis.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Alemtuzumab-Induced Diffuse Alveolar Hemorrhage in a Patient with Multiple Sclerosis (PENNSYLVANIA CONVENTION CENTER, Hall D-E (200 Level), Area A) -  Mar 15, 2020 - Abstract #ATS2020ATS_6406;    
    There is only one published case report that describes the condition in a patient with multiple sclerosis. Our case is unique for the severity of the reaction, as well as complete recovery following discontinuation of alemtuzumab, pulsed steroid therapy, and ventilatory support.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Rituxan (rituximab) / Roche, Lemtrada (alemtuzumab) / Sanofi
    Enrollment closed:  COMBAT-MS: COMparison Between All immunoTherapies for Multiple Sclerosis. (clinicaltrials.gov) -  Mar 13, 2020   
    P=N/A,  N=3526, Active, not recruiting, 
    Our case is unique for the severity of the reaction, as well as complete recovery following discontinuation of alemtuzumab, pulsed steroid therapy, and ventilatory support. Recruiting --> Active, not recruiting
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Zinbryta (daclizumab) / Biogen, AbbVie, Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] EXPENDITURE, UTILIZATION, AND PRICE OF SPECIALTY DRUGS FOR MULTIPLE SCLEROSIS IN THE U.S MEDICAID POPULATION 2008 - 2018 () -  Mar 8, 2020 - Abstract #ISPOR2020ISPOR_1118;    
    Specialty drugs included dimethyl fumarate, fingolimod, teriflunomide, alemtuzumab, natalizumab, ocrelizumab, daclizumab, glatiramer acetate, peginterferonb1A, interferonb1A , and interferon b1B...Intermarket and interbrand competition among the MS specialty drugs were also observed. Medicaid policymakers should investigate new ways to contain further spikes in prescription prices in order to control budget burden on states and government.